Akebia Therapeutics (FRA:AX9) Short-Term Capital Lease Obligation : €4.7 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Short-Term Capital Lease Obligation?

Akebia Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €4.7 Mil.

Akebia Therapeutics's quarterly Short-Term Capital Lease Obligation declined from Sep. 2023 (€4.6 Mil) to Dec. 2023 (€4.1 Mil) but then increased from Dec. 2023 (€4.1 Mil) to Mar. 2024 (€4.7 Mil).

Akebia Therapeutics's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (€4.3 Mil) to Dec. 2022 (€4.5 Mil) but then declined from Dec. 2022 (€4.5 Mil) to Dec. 2023 (€4.1 Mil).

Akebia Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Akebia Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Short-Term Capital Lease Obligation Chart

Akebia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

4.49

4.35

4.25

4.48

4.12

Akebia Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															4.82	4.39	4.56	4.12	4.67

Akebia Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Akebia Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Akebia Therapeutics (FRA:AX9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (FRA:AX9) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

AKBA:USA

Address

245 First Street, Cambridge, MA, USA, 02142

Website

https://www.akebia.com

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Akebia Therapeutics (FRA:AX9) Headlines

No Headlines